Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Monteloeder SL | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study was to establish a formulation, containing both Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) extracts (Metabolaid®) that had significant capacity to activate the AMPK-enzyme and to reduce triglyceride accumulation in the hypertrophied adipocyte model. Then, we assessed the efficacy of this combination in light-to-moderate-overweight subjects under risk of developing metabolic syndrome.
AMP-activated protein kinase (AMPK) has been postulated as a molecular target in the amelioration of obesity-related diseases, where most therapeutic approaches have failed. Plant-polyphenols have shown the capacity to ameliorate obesity-induced metabolic disturbances. A combination of polyphenols (LC-HS) derived from Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) (lemon verbena) (Metabolaid®) was assessed for triglyceride accumulation and AMPK activation in the hypertrophied adipocyte model 3T3-L1. A dietary supplement containing 500 mg of LC-HS was evaluated in a double blind, placebo-controlled and randomized trial in 56 overweight subjects for two months. Anthropometric and circulating biochemical parameters were determined.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Control | Placebo Comparator | 2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks |
|
| Dietetic Supplement Group | Experimental | 2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metabolaid® | Dietary Supplement | 500 mg per day, in fasting conditions. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in body Weight, using a weight scale | In Kg | At the beginning, four weeks and end of the intervention, total eight weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Height, using measuring tape | In cm | At the beginning, four weeks and eight weeks |
| BMI, calculated based on Weight and Height | in kg/m^2 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad Miguel Hernandez de Elche | Elche | Alicante | 03202 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Dietary Supplement |
500 mg per day, in fasting conditions. |
|
| At the beginning, four weeks and eight weeks |
| Waist Circumference, using a measuring tape | in kg/m^2 | At the beginning, four weeks and eight weeks |
| Glucose | Blood Sampling in Fasting conditions, in mg/dl | At the beginning, four weeks and eight weeks |
| Tryglicerides | Blood Sampling in Fasting conditions, in mg/dl | At the beginning, four weeks and eight weeks |
| LDL Cholesterol | Blood Sampling in Fasting conditions, in mg/dl | At the beginning, four weeks and eight weeks |
| HDL Cholesterol | Blood Sampling in Fasting conditions, in mg/dl | At the beginning, four weeks and eight weeks |
| Total Cholesterol | Blood Sampling in Fasting conditions, in mg/dl | At the beginning, four weeks and eight weeks |
| Blood Pressure | Single Blood Pressure measurements, using the Omron M6 Comfort device | At the beginning, four weeks and eight weeks |
| Heart rate | Single Blood Pressure measurements, using the Omron M6 Comfort device | At the beginning, four weeks and eight weeks |
| D009750 |
| Nutritional and Metabolic Diseases |